The anticancer effect of PQ1 in the MMTV-PyVT mouse model

Stephanie N. Shishido, Adélaïde Delahaye, Amanda P. Beck, Thu Annelise Nguyen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Animal models are commonly used to analyze the mechanism of carcinogenesis as well as the development and screening of potent drugs. Here the transgenic strain FVB/N-Tg(MMTV-PyVT)634Mul/J (also known as PyVT) was used as a model system for measuring tumor burden, drug sensitivity, and metastasis of mammary carcinomas. Loss of gap junctional intercellular communication and the down regulation of connexin expression are characteristic of neoplastic cells. The substituted quinoline, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3- trifluoromethyl-phenyloxy)quinolone (PQ1), has been shown to restore GJIC and increase connexin expression in breast cancer cell lines while not affecting normal mammary cells, suggesting that it may provide effective anticancer treatment with less detrimental effects. The PyVT spontaneous mammary tumor mouse model was used to determine the biological and histological effects of PQ1 on tumorigenesis and metastasis at three stages of development: Pretumor, early tumor and late tumor formation. Treatment with PQ1 at all three stages of development significantly reduced tumor growth. PQ1 treatment further increased Cx43 expression during pre- and early-tumor formation, while it prevented an increase in Cx46 expression during late stage tumor formation. This study shows that Cx43 expression and neoplastic cellular growth are inversely related, but that PQ1 can alter tumor growth through targeting gap junction proteins to prove clinical efficacy in the treatment of spontaneous mammary tumors. What's new? Cancer cells commonly turn off intercellular communication via gap junctions. Thus, targeting gap junctions may help focus cancer therapies on the disease cells only, without disturbing healthy cells. This study tested a compound, PQ1, that targets cancer cells by homing in on gap junctions and reactivating them. In a mouse mammary tumor model, the authors showed that treatment with PQ1 at any stage of development significantly reduced tumor growth.

Original languageEnglish (US)
Pages (from-to)1474-1483
Number of pages10
JournalInternational Journal of Cancer
Volume134
Issue number6
DOIs
StatePublished - Mar 15 2014
Externally publishedYes

Fingerprint

Neoplasms
Connexins
Breast Neoplasms
Gap Junctions
Connexin 43
Growth
Carcinogenesis
Neoplasm Metastasis
Preclinical Drug Evaluations
Quinolones
Tumor Burden
Breast
Down-Regulation
Animal Models
Cell Line
Pharmaceutical Preparations
Therapeutics

Keywords

  • connexin
  • gap junctions
  • MMTV-PyVT
  • PQ1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The anticancer effect of PQ1 in the MMTV-PyVT mouse model. / Shishido, Stephanie N.; Delahaye, Adélaïde; Beck, Amanda P.; Nguyen, Thu Annelise.

In: International Journal of Cancer, Vol. 134, No. 6, 15.03.2014, p. 1474-1483.

Research output: Contribution to journalArticle

Shishido, Stephanie N. ; Delahaye, Adélaïde ; Beck, Amanda P. ; Nguyen, Thu Annelise. / The anticancer effect of PQ1 in the MMTV-PyVT mouse model. In: International Journal of Cancer. 2014 ; Vol. 134, No. 6. pp. 1474-1483.
@article{3c4a59559ff0400d958ef5f29ab038aa,
title = "The anticancer effect of PQ1 in the MMTV-PyVT mouse model",
abstract = "Animal models are commonly used to analyze the mechanism of carcinogenesis as well as the development and screening of potent drugs. Here the transgenic strain FVB/N-Tg(MMTV-PyVT)634Mul/J (also known as PyVT) was used as a model system for measuring tumor burden, drug sensitivity, and metastasis of mammary carcinomas. Loss of gap junctional intercellular communication and the down regulation of connexin expression are characteristic of neoplastic cells. The substituted quinoline, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3- trifluoromethyl-phenyloxy)quinolone (PQ1), has been shown to restore GJIC and increase connexin expression in breast cancer cell lines while not affecting normal mammary cells, suggesting that it may provide effective anticancer treatment with less detrimental effects. The PyVT spontaneous mammary tumor mouse model was used to determine the biological and histological effects of PQ1 on tumorigenesis and metastasis at three stages of development: Pretumor, early tumor and late tumor formation. Treatment with PQ1 at all three stages of development significantly reduced tumor growth. PQ1 treatment further increased Cx43 expression during pre- and early-tumor formation, while it prevented an increase in Cx46 expression during late stage tumor formation. This study shows that Cx43 expression and neoplastic cellular growth are inversely related, but that PQ1 can alter tumor growth through targeting gap junction proteins to prove clinical efficacy in the treatment of spontaneous mammary tumors. What's new? Cancer cells commonly turn off intercellular communication via gap junctions. Thus, targeting gap junctions may help focus cancer therapies on the disease cells only, without disturbing healthy cells. This study tested a compound, PQ1, that targets cancer cells by homing in on gap junctions and reactivating them. In a mouse mammary tumor model, the authors showed that treatment with PQ1 at any stage of development significantly reduced tumor growth.",
keywords = "connexin, gap junctions, MMTV-PyVT, PQ1",
author = "Shishido, {Stephanie N.} and Ad{\'e}la{\"i}de Delahaye and Beck, {Amanda P.} and Nguyen, {Thu Annelise}",
year = "2014",
month = "3",
day = "15",
doi = "10.1002/ijc.28461",
language = "English (US)",
volume = "134",
pages = "1474--1483",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - The anticancer effect of PQ1 in the MMTV-PyVT mouse model

AU - Shishido, Stephanie N.

AU - Delahaye, Adélaïde

AU - Beck, Amanda P.

AU - Nguyen, Thu Annelise

PY - 2014/3/15

Y1 - 2014/3/15

N2 - Animal models are commonly used to analyze the mechanism of carcinogenesis as well as the development and screening of potent drugs. Here the transgenic strain FVB/N-Tg(MMTV-PyVT)634Mul/J (also known as PyVT) was used as a model system for measuring tumor burden, drug sensitivity, and metastasis of mammary carcinomas. Loss of gap junctional intercellular communication and the down regulation of connexin expression are characteristic of neoplastic cells. The substituted quinoline, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3- trifluoromethyl-phenyloxy)quinolone (PQ1), has been shown to restore GJIC and increase connexin expression in breast cancer cell lines while not affecting normal mammary cells, suggesting that it may provide effective anticancer treatment with less detrimental effects. The PyVT spontaneous mammary tumor mouse model was used to determine the biological and histological effects of PQ1 on tumorigenesis and metastasis at three stages of development: Pretumor, early tumor and late tumor formation. Treatment with PQ1 at all three stages of development significantly reduced tumor growth. PQ1 treatment further increased Cx43 expression during pre- and early-tumor formation, while it prevented an increase in Cx46 expression during late stage tumor formation. This study shows that Cx43 expression and neoplastic cellular growth are inversely related, but that PQ1 can alter tumor growth through targeting gap junction proteins to prove clinical efficacy in the treatment of spontaneous mammary tumors. What's new? Cancer cells commonly turn off intercellular communication via gap junctions. Thus, targeting gap junctions may help focus cancer therapies on the disease cells only, without disturbing healthy cells. This study tested a compound, PQ1, that targets cancer cells by homing in on gap junctions and reactivating them. In a mouse mammary tumor model, the authors showed that treatment with PQ1 at any stage of development significantly reduced tumor growth.

AB - Animal models are commonly used to analyze the mechanism of carcinogenesis as well as the development and screening of potent drugs. Here the transgenic strain FVB/N-Tg(MMTV-PyVT)634Mul/J (also known as PyVT) was used as a model system for measuring tumor burden, drug sensitivity, and metastasis of mammary carcinomas. Loss of gap junctional intercellular communication and the down regulation of connexin expression are characteristic of neoplastic cells. The substituted quinoline, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3- trifluoromethyl-phenyloxy)quinolone (PQ1), has been shown to restore GJIC and increase connexin expression in breast cancer cell lines while not affecting normal mammary cells, suggesting that it may provide effective anticancer treatment with less detrimental effects. The PyVT spontaneous mammary tumor mouse model was used to determine the biological and histological effects of PQ1 on tumorigenesis and metastasis at three stages of development: Pretumor, early tumor and late tumor formation. Treatment with PQ1 at all three stages of development significantly reduced tumor growth. PQ1 treatment further increased Cx43 expression during pre- and early-tumor formation, while it prevented an increase in Cx46 expression during late stage tumor formation. This study shows that Cx43 expression and neoplastic cellular growth are inversely related, but that PQ1 can alter tumor growth through targeting gap junction proteins to prove clinical efficacy in the treatment of spontaneous mammary tumors. What's new? Cancer cells commonly turn off intercellular communication via gap junctions. Thus, targeting gap junctions may help focus cancer therapies on the disease cells only, without disturbing healthy cells. This study tested a compound, PQ1, that targets cancer cells by homing in on gap junctions and reactivating them. In a mouse mammary tumor model, the authors showed that treatment with PQ1 at any stage of development significantly reduced tumor growth.

KW - connexin

KW - gap junctions

KW - MMTV-PyVT

KW - PQ1

UR - http://www.scopus.com/inward/record.url?scp=84891836589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891836589&partnerID=8YFLogxK

U2 - 10.1002/ijc.28461

DO - 10.1002/ijc.28461

M3 - Article

VL - 134

SP - 1474

EP - 1483

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -